Lumos Signs Binding Term Sheet for A$5.0 million Loan Facility
17 July 2025
Lumos has announced a binding A$5.0 million secured loan facility with major shareholders, Tenmile and Ryder Capital.
This facility strengthens the Company’s balance sheet and is expected to fully fund the Company through to anticipated CLIA waiver for FebriDx® - a key milestone for U.S. market entry.
Lumos Diagnostics CEO & Managing Director, Doug Ward, said:
“This modest funding bridge is being proposed in line with comparable market rates and is designed to help us to maintain momentum as we work towards CLIA waiver and widespread commercialization of FebriDx®, while limiting equity dilution for our shareholders. Lumos appreciates the strong support from our two largest shareholders, Tenmile and Ryder Capital, who have been exceptionally supportive in bringing this strategy together”.
Click to read the ASX release.
This facility strengthens the Company’s balance sheet and is expected to fully fund the Company through to anticipated CLIA waiver for FebriDx® - a key milestone for U.S. market entry.
Lumos Diagnostics CEO & Managing Director, Doug Ward, said:
“This modest funding bridge is being proposed in line with comparable market rates and is designed to help us to maintain momentum as we work towards CLIA waiver and widespread commercialization of FebriDx®, while limiting equity dilution for our shareholders. Lumos appreciates the strong support from our two largest shareholders, Tenmile and Ryder Capital, who have been exceptionally supportive in bringing this strategy together”.
Click to read the ASX release.
